|
市場調查報告書
主要企業：骨質疏鬆症 - 競爭的擴大威脅大型企業和促進技術創新
Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
207802 |
| 內容資訊 |
英文 Pages: 34 |
| 價格 |
|
|
主要企業：骨質疏鬆症 - 競爭的擴大威脅大型企業和促進技術創新 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 34 價格從美金3800起跳。
骨質疏鬆症治療市場為具備實施大型臨床實驗的資金與網羅領域整體銷售力的大型藥廠所寡占的狀態。在針對骨質疏鬆症的行動上，投入1∼2種類的藥劑產品至市場，宣傳其安全性和對病患的便利性，以達到適應症擴大，為一般的企業策略。
本報告，彙整骨質疏鬆症治療市場相關主要企業的品牌生命週期以及產品組合管理策略的徹底考察、Merck & Co.以及Servier公司的骨質疏鬆症產品組合管理策略與其課題的事例研究、活躍於該領域的企業策略動向、近年的重要授權契約的影響、大型企業以及其2005-2010年的業績、今後的商機與課題的對應等最新的調查情報，由下列摘要形式闡述。
概要
報告摘要
- 策略的範圍以及重點
- Datamonitor的主要見解
- 相關報告
企業策略
- 策略概要
- 企業策略的趨勢
- 發展合成代謝治療成為市場的最優先事項
- 藥品重製為普遍的延長品牌壽命策略
- 適應症擴大增加骨質疏鬆症治療藥物的市場性
- 多角化治療的導入可增加收益與降低風險
- 品牌的獨特賣點「投藥的便利性」
- 策略合作・協議的最新情報
- Nycomed增強武田藥品的骨質疏鬆症產品組合
- Warner Chilcott的婦產科專門技術將協助建立於骨質疏鬆症市場上的地位
MERCK & CO.
- 企業策略
- 骨質疏鬆症產品組合評價
- MERCK & CO.骨質疏鬆症產品組的SWOT分析
LES LABORATOIRES SERVIER
- 企業策略
- 骨質疏鬆症產品組合評價
- SERVIER公司骨質疏鬆症產品組的SWOT分析
其他大型企業的產品組合評價
- Novartis
- Amgen
- Pfizer
- Eli Lilly
- GlaxoSmithKline
參考文獻一覽
附錄
圖表
Description
Introduction
The osteoporosis market is dominated by large pharmaceutical companies that can leverage their considerable financial reserves to conduct large-scale clinical trials, and which have the marketing strength needed to penetrate this sector. Osteoporosis companies market one or two drugs for which they promote safety and patient convenience, and pursue indication expansions.
Features and benefits
- In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the osteoporosis market.
- Review Merck & Co.'s and Servier's osteoporosis portfolio management strategies and what challenges these companies are facing.
- Assess trends in corporate strategies of companies active in the osteoporosis arena and understand the impact of key recent licensing deals.
- Identify the leading companies involved in osteoporosis and how their franchises have been performing over 2005-10.
- Learn how companies can respond to future opportunities and challenges in the field.
Highlights
- Developing new technologies to improve compliance remains a popular portfolio management strategy in the osteoporosis market and the latest opportunity is for more conveniently dosed and administered anabolic drugs.
- Merck lost its market leading position due to generic erosion. With two novel therapies in development, the company now has an opportunity to restore its market share. However, the main challenge is to bring these drugs to market while maintaining relationships with key osteoporosis stakeholders.
- Servier has so far maintained a successful standing in Europe by promoting Protelos (strontium ranelate) as a novel effective and safe alternative therapy to bisphosphonates. However, in spite of the possible launch of a follow-on product, long term growth prospects will be hindered by future competition from generic strontium ranelate.
Your key questions answered
- Which are the leading companies in the osteoporosis market?
- How successful are the portfolio management strategies most widely used in the osteoporosis market?
- How is Merck & Co. attempting to regain its leading position?
- What makes Servier's osteoporosis offering unique?
- What are the main challenges companies are facing in this therapy area?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
COMPANY STRATEGIES
- Strategic overview
- Trends in corporate strategy
- Developing anabolic treatments becomes a priority in the market
- Reformulations are popular brand lifecycle extension strategies
- Indication expansions increase the market potential of osteoporosis drugs
- Multiple therapy offerings can increase returns and lower risk
- Dosing convenience as a unique selling point of their brands
- Recent strategic partnerships and deals
- Nycomed bolsters Takeda's osteoporosis portfolio
- Warner Chilcott's women's health expertise will help build its presence in the osteoporosis market
MERCK & CO.
- Corporate strategy
- Osteoporosis portfolio assessment
- Merck loses its market leading position due to poor portfolio management strategy
- High risk first-in-class pipeline products will reward Merck
- SWOT analysis for Merck's osteoporosis portfolio
LES LABORATOIRES SERVIER
- Corporate strategy
- Osteoporosis portfolio assessment
- Servier promotes safety data to exploit concerns regarding other therapies
- Servier in-licenses NBS101 to maintain its osteoporosis franchise but this is unlikely to be sufficient
- Servier shows commitment to the European osteoporosis community
- SWOT analysis for Servier's osteoporosis portfolio
PORTFOLIO REVIEW OF OTHER LEADING COMPANIES
- Novartis
- Continued interest in the market is reflected in the pipeline activity
- Amgen
- Investing heavily in building its presence in the osteoporosis community to drive Prolia's uptake
- Amgen is developing a novel anabolic compound
- Pfizer
- Pfizer attempts to redefine the SERM market
- Eli Lilly
- Eli Lilly to lose leading position due to poor pipeline
- GlaxoSmithKline
- GlaxoSmithKline maintains interest in the osteoporosis market
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
- PharmaVitae Explorer database
- Conferences attended
- Report methodology
|
